<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122629</url>
  </required_header>
  <id_info>
    <org_study_id>ANRSHC03 BITRI</org_study_id>
    <nct_id>NCT00122629</nct_id>
  </id_info>
  <brief_title>Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders</brief_title>
  <official_title>Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <brief_summary>
    <textblock>
      Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to&#xD;
      increase sustained virological response (SVR) rates in HCV non-responders to a standard&#xD;
      interferon/ribavirin combination.&#xD;
&#xD;
      Patients with hepatitis C virus infection were eligible if they had failed to respond to a&#xD;
      single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was&#xD;
      defined as persistent HCV RNA in the serum during the last month of treatment.&#xD;
&#xD;
      This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and&#xD;
      amantadine or a placebo for 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple antiviral therapy with peg-interferon-alfa/ribavirin + amantadine was suggested to&#xD;
      increase sustained virological response (SVR) rates in HCV non-responders to a standard&#xD;
      interferon/ribavirin combination.&#xD;
&#xD;
      The aim of this study is to determine if the addition of amantadine to PEG-IFN/ribavirin&#xD;
      enhances SVR.&#xD;
&#xD;
      This study is a double blind, comparative, prospective multicenter, randomized study.&#xD;
      Patients are recruited from 23 hepatology centers in France. The protocol was approved by the&#xD;
      French ethical committee and all patients provided written informed consent. Eligible&#xD;
      subjects are randomly assigned to the two treatment groups in equal proportions. The&#xD;
      randomization process is generated by the Department of Biostatistics, Hospices Civils de&#xD;
      Lyon, Lyon, France.&#xD;
&#xD;
      Main inclusion criteria are: elevated ALT, detectable HCV RNA, Metavir score over or equal to&#xD;
      A1F1 and below or equal to F3. Patients received PEG-IFN 1.5µg/kg/week, ribavirin&#xD;
      800-1200mg/day and amantadine 200mg/day or placebo during 48 weeks.&#xD;
&#xD;
      The primary endpoint is a sustained virological response, defined as an undetectable HCV-RNA&#xD;
      24 weeks after treatment discontinuation (week 72). Secondary endpoints are the biochemical&#xD;
      response at week 72 defined as ALT normalization; histological benefit; tolerance; and&#xD;
      virological and biochemical responses during therapy at weeks 12, 24 and 48.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2000</start_date>
  <completion_date>May 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation at week 72</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical response at week 72 defined as ALT normalization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological benefit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological and biochemical responses during therapy at weeks 12, 24 and 48</measure>
  </secondary_outcome>
  <enrollment>405</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peg-interferon alfa-2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive anti-HCV antibody test&#xD;
&#xD;
          -  Patients who did not respond to treatment with standard interferon + ribavirin (HCV&#xD;
             RNA+ by PCR in the last month of treatment)&#xD;
&#xD;
          -  Compensated liver disease&#xD;
&#xD;
          -  Neutrophil count over or equal to1000/mm3&#xD;
&#xD;
          -  Platelet count over or equal to 100 giga/L&#xD;
&#xD;
          -  Haemoglobin over or equal to 10g/dL&#xD;
&#xD;
          -  Patients had to have undergone a post-treatment liver biopsy within a year, showing a&#xD;
             METAVIR histological score over or equal to A1F1, without cirrhosis (fibrosis score&#xD;
             below F4)&#xD;
&#xD;
          -  ALT over N and HCV RNA+ at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-infection with hepatitis B or human immunodeficiency virus&#xD;
&#xD;
          -  Any other cause of liver disease&#xD;
&#xD;
          -  Active drug abuse, active alcohol consumption above 40g/day&#xD;
&#xD;
          -  Organ grafts&#xD;
&#xD;
          -  Presence of hepatocellular carcinoma&#xD;
&#xD;
          -  Cardiovascular, metabolic, renal, haematological, neurological or psychiatric disease&#xD;
&#xD;
          -  Patients with previous amantadine use&#xD;
&#xD;
          -  Systemic immunosuppressive or antiviral treatment during the last 24 weeks and those&#xD;
             with a history of interferon and/or ribavirin intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Trepo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hépato-Gastroentérologie Hopital Hôtel-Dieu LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. ADELEINE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratoire d'Informatique Médicale Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie Hopital Hotel Dieu</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>July 20, 2005</study_first_submitted>
  <study_first_submitted_qc>July 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>July 28, 2005</last_update_submitted>
  <last_update_submitted_qc>July 28, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2005</last_update_posted>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>peginterferon alfa-2b</keyword>
  <keyword>ribavirin</keyword>
  <keyword>Amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

